This content is password-protected. To view it, please enter the password below.

Dr. Mary-Margaret Keating is a hematologist and assistant professor of medicine, in the Division of Hematology at the QEII Health Science Center in Halifax, Nova Scotia. She has a clinical focus in lymphoma and is involved in selecting and overseeing clinical trials for this disease area.

She earned a master’s in medical education from Acadia University and has a passion for teaching medical students, residents and patients. She is the program director for the hematology residency training program and the unit head for the skilled clinician course at Dalhousie Medical School.

Dr. Alissa Visram is a hematologist at the Ottawa Hospital and an assistant professor within the Department of Medicine. She completed her hematology training at Dalhousie University in Nova Scotia, and her subspecialty clinical and research fellowship in plasma cell disorders at Mayo Clinic. Dr. Visram holds a Masters in Public Health and Epidemiology from Harvard University.

She joined faculty in Ottawa in September of 2021 as a clinician investigator. Her clinical research is centered on understanding and improving health outcomes of patients with plasma cell disorders and developing cost-effective and efficacious immunotherapies for patients with multiple myeloma.

Dr. Julie Bergeron is an Associate Professor of Medicine at the University of Montreal. She works in the Hematology Division at CEMTL, Hôpital Maisonneuve-Rosemont and Institut universitaire d’Hémato-Oncologie et Thérapie cellulaire (IHOT).

After her training in hematology she completed a post doctoral fellowship in Paris at Necker-Enfants-Malades in Molecular Biology of Hematologic Malignancies. Her clinical practice is focused on Acute Leukemias, both lymphoblastic and myeloblastic. She has acted as the site or national PI in multiple clinical trials in the field of Acute Leukemias. She also has a laboratory practice in the Molecular Diagnosis Laboratory and is head of the Hematology Laboratory Service of OPTILAB CHUM. 

Dr. Isabelle Fleury is a hematologist and medical oncologist who worked at Maisonneuve-Rosemont Hospital before joining the CHU de Québec in 2025. She completed a bachelor’s degree in microbiology and pursued a master’s degree in biomedical sciences concurrently with her medical training. She also completed a lymphoma fellowship at Hôpital Saint-Louis in Paris. She is a Clinical Associate Professor at Université Laval.
 
She established the fellowship program in lymphoma and immune effector cells at Université de Montréal, has participated in clinical trials involving CAR-T therapies since 2015 and played a pivotal role in implementing CAR-T therapy as a standard of care in the province of Quebec since its introduction in 2019.
 
Her primary interest is improving the care of patients with lymphoma. She is actively involved in clinical research, participating in phase I to III clinical trials. Dr. Fleury is also the instigator of the C3i Lymphoma Registry, which collects clinical and bioclinical data to better understand lymphoma in real-world settings.

Dr. Diego Villa is Clinical Associate Professor at the University of British Columbia and a medical oncologist at the BC Cancer – Vancouver Cancer Center. He is involved in the care of patients with lymphoid malignancies and breast cancer. His research interests include the management of transformed indolent lymphomas, management of mantle cell lymphoma, primary and secondary CNS lymphomas, and the role of PET/CT in aggressive lymphoma. Dr. Villa has ongoing research collaborations with Canadian, American, European, and Australian lymphoma groups. He is also the local principal investigator for various international lymphoma and breast cancer clinical trials open in Vancouver. He actively participates in the teaching of medical students, residents, and fellows at BCCA and VGH, and is the faculty coordinator for the medical oncology rotation at BCCA for the UBC Internal Medicine Residency Program. Dr. Villa is a member of the UBC Medical
Oncology Residency Training Program committee and its Competence by Design subcommittee.

Dr. Dawn Maze is a clinician investigator at the Princess Margaret Cancer Centre and an Assistant Professor in the Department of Medicine at the University of Toronto. She is a member of the Leukemia Site Group and the Myeloproliferative Neoplasms (MPN) Program and has a clinical research interest in myeloid malignancies. Her primary research focus is in MPN, particularly in risk stratification and management approaches early in the disease course and in the adolescent/young adult population. 

She is particularly interested in optimizing pregnancy outcomes in this population. She is also actively involved in clinical trials and projects aiming to refine risk stratification in acute myeloid leukemia. Dr. Maze is an active member of the Canadian MPN Group. She is the Medical Director for the Malignant Hematology Day Unit at Princess Margaret and the Program Director for the Leukemia Fellowship Program.

Dr. Robert Puckrin is a Hematologist and Clinician Investigator at the Arthur Child Comprehensive Cancer Centre, Alberta Blood and Marrow Transplant Program, and the University of Calgary in Calgary, Canada.

Having obtained his medical degree from McGill University, he completed Internal Medicine training at the University of Toronto and subsequent training in Hematology and Hematopoietic Cell Transplantation and Cellular Therapy at the University of Calgary. His main clinical and research interests are in lymphoma, cellular therapy, clinical trials, and real-world data.